Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

被引：39

作者：

Sequist, Lecia V. ^{[1
]}

Cassier, Phillippe ^{[2
]}

Varga, Andrea ^{[3
]}

Tabernero, Josep ^{[4
]}

Schellens, Jan H. ^{[5
]}

Delord, Jean-Pierre ^{[6
]}

LoRusso, Patricia ^{[7
]}

Camidge, D. Ross ^{[8
]}

Hidalgo Medina, Manuel ^{[9
]}

Schuler, Martin ^{[10
]}

Campone, Mario ^{[11
]}

Tian, G. Gary ^{[12
]}

Wong, Steven ^{[13
]}

Corral, Jesus ^{[14
]}

Isaacs, Randi ^{[15
]}

Sen, Suman K. ^{[16
]}

Porta, Diana Graus ^{[17
]}

Kulkarni, Swarupa G. ^{[16
]}

Lefebvre, Caroline ^{[18
]}

Wolf, Juergen ^{[19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Ctr Leon Berard, F-69373 Lyon, France

[3] Inst Gustave Roussy, Villejuif, France

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Netherlands Canc Inst, Amsterdam, Netherlands

[6] Inst Claudius Regaud, Toulouse, France

[7] Karmanos Canc Inst, Detroit, MI USA

[8] Univ Colorado, Aurora, CO USA

[9] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain

[10] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany

[11] Ctr Rene Gauducheau, F-44035 Nantes, France

[12] West Clin, Memphis, TN USA

[13] UCLA Med Ctr, Los Angeles, CA USA

[14] Univ Hosp Virgen del Rocio, Seville, Spain

[15] Novartis OTM, E Hanover, NJ USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] NIBR Oncol, Basel, Switzerland

[18] Novartis OTM, Basel, Switzerland

[19] Univ Hosp Cologne, Cologne, Germany

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT326

引用

页数：2

共 50 条

[31] Preclinical profile of BAY 1163877-a selective pan-FGFR inhibitor in phase 1 clinical trial
Heroult, Melanie
Ellinghaus, Peter
Sieg, Christian
Brohm, Dirk
Gruenewald, Sylvia
Collin, Marie-Pierre
Boemer, Ulf
Lobell, Mario
Huebsch, Walter
Ocker, Matthias
Ince, Stuart
Haegebarth, Andrea
Jautelat, Rolf
Hess-Stumpp, Holger
Brands, Michael
Ziegelbauer, Karl
CANCER RESEARCH, 2014, 74 (19)
[32] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
Xu, Jian-Ming
Wang, Yan
Shen, Lin
Gong, Jifang
Huang, Cheng
Ye, Chen Yang
Yang, Li
Sai, Yang
Mu, Hua
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[33] DRUG INTERACTION POTENTIAL OF INFIGRATINIB (BGJ398), A POTENT AND SELECTIVE FGFR1-3 INHIBITOR, IN HEALTHY VOLUNTEERS (HV): PHARMACOKINETICS (PK) AND SAFETY.
Reyes, M.
Belcher, V.
Hormel, K.
Chung, D.
Guptha, S.
Zamora, C.
Atiee, G.
Roupe, K.
Zhang, W.
Moran, S.
Martin, D.
Stark, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S49 - S50
[34] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF ARQ 087, A NOVEL PAN-FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING INTRAHEPATIC CHOLAN-GIOCARCINOMA.
Savage, R.
Trinh, M.
Dupuis, M.
Marier, J. F.
Schwartz, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S77 - S77
[35] A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
Javle, Milind M.
Shroff, Rachna T.
Zhu, Andrew
Sadeghi, Saeed
Choo, Supin
Borad, Mitesh J.
Lowery, Maeve Aine
El-Khoueiry, Anthony
Macarulla, Teresa
Philip, Agop Philip
Oh, Do-Youn
Van Cutsem, Eric
Yeh, Kun-Huei
Isaacs, Randi
McGarry, Carolyn
Sen, Suman
Bekaii-Saab, Tanios S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[36] Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Pal, Sumanta K.
Rosenberg, Jonathan E.
Hoffman-Censits, Jean H.
Berger, Raanan
Quinn, David I.
Galsky, Matthew D.
Wolf, Juergen
Dittrich, Christian
Keam, Bhumsuk
Delord, Jean-Pierre
Schellens, Jan H. M.
Gravis, Gwenaelle
Medioni, Jacques
Maroto, Pablo
Sriuranpong, Virote
Charoentum, Chaiyut
Burris, Howard A.
Grunwald, Viktor
Petrylak, Daniel
Vaishampayan, Ulka
Gez, Eliahu
De Giorgi, Ugo
Lee, Jae-Lyun
Voortman, Jens
Gupta, Sumati
Sharma, Sunil
Mortazavi, Amir
Vaughn, David J.
Isaacs, Randi
Parker, Katie
Chen, Xueying
Yu, Kun
Porter, Dale
Porta, Diana Graus
Bajorin, Dean F.
CANCER DISCOVERY, 2018, 8 (07) : 812 - 821
[37] Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations
Pal, Sumanta K.
Rosenberg, Jonathan E.
Keam, Bhumsuk
Wolf, Juergen
Berger, Raanan
Dittrich, Christian
Hoffman-Censits, Jean H.
Quinn, David
van der Noll, Ruud
Burris, Howard A.
Galsky, Matt D.
Gravis, Gwenaelle
Lee, Jae-Lyun
Medioni, Jacques
Mortazavi, Amir
Maroto, Pablo
Parker, Katie
Chen, Xueying
Isaacs, Randi
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[38] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
Bahleda, R.
Meric-Bernstam, F.
Goyal, L.
Tran, B.
He, Y.
Yamamiya, I
Benhadji, K. A.
Matos, I
Arkenau, H-T
ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
[39] Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors
Bahleda, Rastislav
Meric-Bernstam, Funda
Goyal, Lipika
Tran, Ben
He, Helen
Winkler, Robert
Hierro, Cinta
Arkenau, Hendrik-Tobias
CANCER RESEARCH, 2018, 78 (13)
[40] Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines
Packer, L.
Geng, X.
Bonazzi, V.
Mahon, C.
Ju, R.
Stephenson, S.
Pollock, P.
EUROPEAN JOURNAL OF CANCER, 2016, 61 : S148 - S148

← 1 2 3 4 5 →